Description
- A small molecule of the quinolinium derivative class — not a peptide, unlike most of the catalog.
- Full name: 5-amino-1-methylquinolinium.
- A selective inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT).
- NNMT methylates nicotinamide, diverting it from the pathway leading to NAD+ production.
- Published work describes that inhibiting NNMT increases the availability of nicotinamide in models, and with it cellular NAD+ levels.
- In models of obesity, increased NNMT expression in adipose tissue is described — this is where the interest in inhibiting it comes from.
- The mechanism is indirect: it does not raise NAD+ by supplying substrate, but by unblocking its consumption down another pathway.
- NAD+ metabolism and its regulation.
- NNMT expression in adipose tissue.
- Energy metabolism of adipocytes.
- Skeletal muscle and regenerative capacity in models of ageing.
Studied in the context of the same pathway as NAD+ and MOTS-C, both in the catalog.
The published data come from in vitro models and animal studies, chiefly mouse models of obesity. Clinical studies in humans are still at the very beginning — this is a substance at an early stage of research.
NOT FOR CONSUMPTION. FOR RESEARCH USE ONLY. Reference material intended solely for laboratory and research use. It is not a medicine, food supplement, food or cosmetic product, and it is not intended for diagnosis, treatment, ingestion, inhalation, injection or any other administration to humans or animals. The information below summarises published research; it is not a claim about this article and not instructions for use. We provide no dosage or health guidance.
